# Caplyta - (10.5 and 21 mg ; Capsule, Oral)

| | | | |
|---|---|---|---|
| **Generic Name** | Lumateperone Tosylate | **Innovator** | Intra-Cellular |
| **Dosage** | 10.5 and 21 mg ; Capsule, Oral | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | More Than 5 | **Known Para IV Filers** | More Than 5 |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | Less Than 5 |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | CAPLYTA is an atypical antipsychotic indicated for the treatment of: • Schizophrenia in adults. • Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

# Caplyta - (42 mg ; Capsule, Oral)

| | | | |
|---|---|---|---|
| **Generic Name** | Lumateperone Tosylate | **Innovator** | Intra-Cellular |
| **Dosage** | 42 mg ; Capsule, Oral | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | More Than 5 | **Known Para IV Filers** | More Than 5 |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | More Than 5 |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | CAPLYTA is an atypical antipsychotic indicated for the treatment of: • Schizophrenia in adults. • Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.